[go: up one dir, main page]

UY26833A1 - USE OF PARAPOXVIRUS OVIS VAPES AGAINST ORGAN FIBROSIS - Google Patents

USE OF PARAPOXVIRUS OVIS VAPES AGAINST ORGAN FIBROSIS

Info

Publication number
UY26833A1
UY26833A1 UY26833A UY26833A UY26833A1 UY 26833 A1 UY26833 A1 UY 26833A1 UY 26833 A UY26833 A UY 26833A UY 26833 A UY26833 A UY 26833A UY 26833 A1 UY26833 A1 UY 26833A1
Authority
UY
Uruguay
Prior art keywords
vapes
liver
organ fibrosis
parapoxvirus ovis
against organ
Prior art date
Application number
UY26833A
Other languages
Spanish (es)
Inventor
Dr Olaf Weber
Dr Claudia Hirth-Dietrich
Dr Tobias Schlapp
Dra Angela Siegling
Gudrun Theiss
Andreas Knorr
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Priority to UY26833A priority Critical patent/UY26833A1/en
Publication of UY26833A1 publication Critical patent/UY26833A1/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere al uso en humanos de parapoxvirus inactivos en la profilaxis y tratamiento de enfermedades que están acompanadas por un aumento de la concreción de colágeno, pudiendo concernir tanto a órganos internos, como por ejemplo el hígado, como también a la piel y sus anexos. Se refiere especialmente a fibrosis hepática o cirrosis hepática como consecuencia de hepatitis viral o enfermedades hepáticas inducidas por etanol, así como fibrosis quística.The present invention relates to the use in humans of inactive parapoxviruses in the prophylaxis and treatment of diseases that are accompanied by an increase in collagen concretion, being able to concern both internal organs, such as the liver, as well as the skin and its annexes. It especially refers to liver fibrosis or liver cirrhosis as a result of viral hepatitis or ethanol-induced liver diseases, as well as cystic fibrosis.

UY26833A 2001-07-11 2001-07-11 USE OF PARAPOXVIRUS OVIS VAPES AGAINST ORGAN FIBROSIS UY26833A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
UY26833A UY26833A1 (en) 2001-07-11 2001-07-11 USE OF PARAPOXVIRUS OVIS VAPES AGAINST ORGAN FIBROSIS

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
UY26833A UY26833A1 (en) 2001-07-11 2001-07-11 USE OF PARAPOXVIRUS OVIS VAPES AGAINST ORGAN FIBROSIS

Publications (1)

Publication Number Publication Date
UY26833A1 true UY26833A1 (en) 2002-01-31

Family

ID=38812466

Family Applications (1)

Application Number Title Priority Date Filing Date
UY26833A UY26833A1 (en) 2001-07-11 2001-07-11 USE OF PARAPOXVIRUS OVIS VAPES AGAINST ORGAN FIBROSIS

Country Status (1)

Country Link
UY (1) UY26833A1 (en)

Similar Documents

Publication Publication Date Title
NO20074824L (en) Extension of time to disease progression or survival in cancer patients
SG163517A1 (en) Antiviral compounds and methods
MX2010003916A (en) Spiropyrrolidines and their use against hcv and hiv infection.
CY1111050T1 (en) PHOSPHONES, MONO-PHOSPHONAMIDES, BISPHOSPHONAMIDES FOR THE TREATMENT OF VIRUS DISEASES
WO2007081517A3 (en) Anti-viral compounds
NO20074361L (en) Lacosamide for "add-on" therapy
NO20085243L (en) Pharmaceutical composition for the treatment of viral infections and / or tumor diseases through inhibition of protein folding and protein degradation
BR0208142A (en) Combinations comprising an antidiarrheal agent and epothilone or epothilone derivative
ITMI20041550A1 (en) USE OF PROBIOTIC BACTERIA FOR THE PREPARATION OF TOPICAL COMPOSITIONS FOR THE PROTECTION OF THE EPIDERMIS
CY1110437T1 (en) USE OF KASTANOSPERMIN PRODUCTS FOR THE TREATMENT OF USITIS C
MY137766A (en) Exemestane as chemopreventing agent
NO20055130D0 (en) Aminocyclohexyl ether compounds and their use
DE60330708D1 (en) VACCINE AGAINST WEST NILE VIRUS
PE20081215A1 (en) IDENTIFICATION AND CHARACTERIZATION OF HCV REPLICATION VARIANTS WITH LOWER SUSCEPTIBILITY TO HCV-796, AND RELATED METHODS
AR028800A1 (en) USE OF PARAPOXVIRUS OVIS VAPES AGAINST ORGAN FIBROSIS
NO20076405L (en) Use of 24-nor-UDCA
BR0108499A (en) Hepatitis c therapeutic agent
UA85379C2 (en) Recombinant poxvirus, comprising at least two ati promotors of cowpox
HK1054329A1 (en) Use of strains of parapoxvirus ovis for producing antiviral medicaments and medicaments against cancer
GT200600262A (en) USE OF SANGLIFERINE IN HCV (HEPATITIS VIRUS "C")
MXPA02011969A (en) Methods of treating viral diseases with il-18 and il-18 combinations.
UY27827A1 (en) COMPOSITIONS AND THERAPEUTIC USE
UY26833A1 (en) USE OF PARAPOXVIRUS OVIS VAPES AGAINST ORGAN FIBROSIS
IL164179A0 (en) Expression of genes in modified vaccinia virus ankara by using the cowpox ati promoter
TW200716226A (en) Compositions comprising actinidia and methods of use thereof

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20141021